The Food and Drug Administration on Monday took the extraordinary step of issuing a lengthy statement on an unapproved drug, rejecting claims made by the troubled drug maker CytoDyn about its failed antibody treatment for Covid-19.
CytoDyn’s CEO, Nader Pourhassan, has repeatedly touted the potential of the drug, leronlimab, on conference calls, YouTube videos, and in press releases, saying the treatment was shown to have saved lives in clinical trials.
The FDA said it had determined otherwise.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect